Global Private Group has invested in Biopharmaceutical Company dedicated to the development of enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than forty rare inherited diseases.
Series D financing round for the company raised USD 49.5M, Global Private Group was the sole arranger.
Satisfied Users & 
Approved Press Releases
